Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY4R | P50391 | 8/20 | 0.35 |
| ▸ | NPY1R | P25929 | 6/20 | 0.35 |
| ▸ | MMP2 | P08253 | 2/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | KCNB1 | Q14721 | 3/20 | 0.34 |
| ▸ | NPY2R | P49146 | 5/20 | 0.33 |
| ▸ | NPY5R | Q15761 | 5/20 | 0.33 |
| ▸ | SYK | P43405 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.33 |
| ▸ | FNTA | P49354 | 1/20 | 0.33 |
| ▸ | FNTB | P49356 | 1/20 | 0.33 |
| ▸ | PGGT1B | P53609 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10260923 | 0.93 | NPY4R (0.39) | NPY4RNPY1RMMP2TSHRKCNB1 | |
| SCHEMBL21371580 | 0.90 | NPY4R (0.39) | NPY4RNPY1RMMP2TSHRKCNB1 | |
| SCHEMBL13973705 | 0.87 | NPY4R (0.39) | NPY4RNPY1RMMP2TSHRKCNB1 | |
| SCHEMBL19445635 | 0.86 | KCNB1 (0.40) | NPY4RNPY1RMMP2TSHRKCNB1 | |
| SCHEMBL12444369 | 0.86 | NPY4R (0.42) | NPY4RNPY1RMMP2TSHRKCNB1 | |
| SCHEMBL10262675 | 0.86 | NPY4R (0.42) | NPY4RNPY1RMMP2TSHRKCNB1 | |
| SCHEMBL15138938 | 0.86 | NPY4R (0.42) | NPY4RNPY1RMMP2TSHRKCNB1 | |
| SCHEMBL16285905 | 0.86 | NPY4R (0.42) | NPY4RNPY1RMMP2TSHRKCNB1 | |
| SCHEMBL10262445 | 0.86 | NPY4R (0.38) | NPY4RNPY1RMMP2TSHRKCNB1 | |
| SCHEMBL21372068 | 0.86 | NPY4R (0.38) | NPY4RNPY1RMMP2TSHRKCNB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10603294-B2 | Compounds for use in treatment of mucositis | INNOVATION PHARMACEUTICALS INC. (US) | 2020-03-31 | — | — | US | disclosed |
| US-20190282521-A1 | Compounds For Use In Treatment Of Mucositis | POLYMEDIX, INC. | 2019-09-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10603294-B2 | Compounds for use in treatment of mucositis | MUC1, FUT6, MMP8 | NPY4R 4770/4885NPY1R 4756/4885MMP2 367/4885 |
| US-20190282521-A1 | Compounds For Use In Treatment Of Mucositis | MUC1, FUT6, MMP8 | NPY4R 4770/4885NPY1R 4756/4885MMP2 367/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.